Latest Breaking News On - Noboru yamamoto - Page 1 : comparemela.com

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPa Monoclonal Antibody

OSE Immunotherapeutics Announces First Clinical Results for BI 770371, a Novel Anti-SIRPa Monoclonal Antibody
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Biberach an der rissBaden wübergUnited statesUniversity hospitalGunther kretschmarIhre chancenFlorence portejoieNoboru yamamotoJavier ferradaMartine gutierrezToshihiko doiManishr patelNicolas poirierRahima jamalStephan wojciekowskiIndiens wirtschaft

Zongertinib Proves Clinically Active With Low Rate of EGFR-Mediated AEs in HER2-Mutant Solid Tumors

Treatment with at least 90 μg/kg of the novel DLLC-targeting T-cell–engager BI 764532 was well tolerated and led to tumor shrinkage in patients with small cell lung cancer and neuroendocrine carcinoma.

United statesNoboru yamamotoNational cancer center hospitalDepartment of experimental therapeuticsLung cancerExperimental therapeuticsMiddle eastWorld conference on lung cancerHer2 mutant solid tumors

Renesas Electronics : The Voting Result of the 21st Annual General Meeting of Shareholders (English Translation of the Extraordinary Report)

【Cover sheet】【Title】【Submit to】 . | April 7, 2023

Chuo kuKoto kuNihombashi kabutochoSelena loh lacroixJiro iwasakiTakuya hiranoYukitake hashiguchiHidetoshi shibataNoboru yamamotoRenesas electronics corporationEmployee share purchase plan for the companyCompany nameHead of kanto local finance bureauCorporate governance departmentTokyo stock exchange incRegistered address

Renesas Announces Executive Personnel Changes – Consumer Electronics Net

Renesas Announces Executive Personnel Changes – Consumer Electronics Net
consumerelectronicsnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from consumerelectronicsnet.com Daily Mail and Mail on Sunday newspapers.

Tomoko mizunoJiro iwasakiTakuya hiranoKazuki fukudaKazuyoshi yamazakiKyoko okamotoArunjai mittalHidetoshi shibataNoboru yamamotoSelena loh lacroixHyperion solutions corporationOracle corporationHyperion solutions japanEnterprise serviceBusiness marketing divisionGlobal service partner business

Chordia Therapeutics Announces Interim Results of the Phase 1 Clinical Trial of CLK Inhibitor CTX-712 at the 2022 ASCO Annual Meeting

/PRNewswire/ Chordia Therapeutics Inc. ("Chordia"), a biotech company engaged in the research and development of novel therapies for cancers, today.

United statesNoboru yamamotoHiroshi miyakeNational cancer center hospitalChordia therapeutics incPrnewswire chordia therapeutics incDepartment of experimental therapeuticsShonan health innovation parkAmerican societyClinical oncologyExperimental therapeuticsPrincipal investigatorFirst in human phaseRefractory malignantArginine rich proteinsChordia therapeutics